TLR3 and neoplasm: Importantly, in an ovarian cancer model, in situ co-administration of CD40 and TLR3 agonists has induced the polarization of tumor-infiltrating DCs into an immune stimulatory phenotype that was able to produce type I IFN and IL-12 p70, resulting in tumor remission (Scarlett et al., 2009).